Skip to main content

Table 3 Observed and net 8-year survival rates (% (95% CI)) by histological type and Charlson Comorbidity Index (CCI) grade for adenocarcinomas, squamous cell carcinomas and small cell cancers diagnosed in 2004 and recruited among 10 French cancer registries

From: Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries

CCI grade Adenocarcinomas (n = 646) Squamous cell cancers (n = 524) Small cell cancers (n = 233)
Observed survival Net survival Observed survival Net survival Observed survival Net survival
0 12.3% (9.0–16.2%) 13.7% (9.7–17.8%) 12.3% (8.2–17.3%) 14.1% (8.7–19.4%) 3.7% (1.2–8.6%) 4.1% (0.2–8.0%)
1 13.2% (8.5–19.0%) 15.1% (9.1–22.2%) 10.2% (6.1–15.5%) 12.6% (6.8–18.4%) 3.3% (0.6–10.1%) 3.5% (0.0–7.8%)
2 11.9% (6.1–19.8%) 14.0% (5.7–22.2%) 13.7% (7.2–22.3%) 17.4% (7.9–26.8%) 3.2% (0.2–14.1%) 3.3% (0.0–8.4%)
≥ 3 1.6% (0.1–7.6%) 1.7% (0.0–4.5%) 8.0% (3.3–15.5%) 10.1% (2.3–17.9%) 0.0% (0.0–0.0%) 0.0% (0.0–1.0%)